A study of 3,243 Japanese patients found that observed fixed-dose nivolumab billing was a median of 89,540 yen higher per ...
The Food and Drug Administration on Thursday fully approved the Alzheimer’s drug Leqembi, amid concerns about its safety, cost and accessibility. The move marks the first time that a drug meant to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results